The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Open accessAbstract
Purpose: To develop evidence-based guidelines, based on a systematic review, for endocrine therapy for postmenopausal women with hormone receptor–positive breast cancer. Methods: A literature search identified relevant randomized trials. Databases searched included MEDLINE, PREMEDLINE, the Cochrane Collaboration Library, and those for the Annual Meetings of the American Society of Clinical Oncology (ASCO) and the San Antonio Breast Cancer Symposium (SABCS). The primary outcomes of interest were disease-free survival, overall survival, and time to contralateral breast cancer. Secondary outcomes included adverse events and quality of life. An expert panel reviewed the literature, especially 12 major trials, and developed updated recommendations. Results: An adjuvant treatment strategy incorporating an aromatase inhibitor (AI) as primary (initial endocrine therapy), sequential (using both tamoxifen and an AI in either order), or extended (AI after 5 years of tamoxifen) therapy reduces the risk of breast cancer recurrence compared with 5 years of tamoxifen alone. Data suggest that including an AI as primary monotherapy or as sequential treatment after 2 to 3 years of tamoxifen yields similar outcomes. Tamoxifen and AIs differ in their adverse effect profiles, and these differences may inform treatment preferences. Conclusion: The Update Committee recommends that postmenopausal women with hormone receptor–positive breast cancer consider incorporating AI therapy at some point during adjuvant treatment, either as up-front therapy or as sequential treatment after tamoxifen. The optimal timing and duration of endocrine treatment remain unresolved. The Update Committee supports careful consideration of adverse effect profiles and patient preferences in deciding whether and when to incorporate AI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Unequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationHorne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Self-citationCoombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Self-citationEndocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Coombes, R., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., Jassem, J., Van de Velde, C., Delozier, T., Alvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 907
Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., Hilfrich, J., Kwasny, W., Menzel, C., Samonigg, H., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67059-6 · Cited by 879
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Self-citationMeta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 813
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Self-citationAmerican Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Fisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810818 · Cited by 496
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., & Asnis-Alibozek, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5451 · Cited by 482
Self-citationCrew, K. D., Greenlee, H., Capodice, J., Raptis, G., Brafman, L., Fuentes, D., Sierra, A., & Hershman, D. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7573 · Cited by 478
Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Kainberger, F., Kässmann, H., Piswanger-Sölkner, J. C., Seifert, M., Ploner, F., Menzel, C., Dubsky, P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70204-3 · Cited by 396
Missed Opportunities: Racial Disparities in Adjuvant Breast Cancer Treatment
Bickell, N. A., Wang, J. J., Oluwole, S., Schrag, D., Godfrey, H., Hiotis, K., Mendez, J., & Guth, A. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5799 · Cited by 363
Mamounas, E. P., Jeong, J.-H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., Eisen, A., Fehrenbacher, L., Farrar, W. B., Atkins, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0228 · Cited by 341
Self-citationViale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S. G., Öhlschlegel, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0829 · Cited by 340
Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., & Perez, E. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3744 · Cited by 321
Jakesz, R., Greil, R., Gnant, M., Schmid, M., Kwasny, W., Kubista, E., Mlineritsch, B., Tausch, C., Stierer, M., Hofbauer, F., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm246 · Cited by 312
Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.029 · Cited by 310
Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300
Early discontinuation of tamoxifen: A Lesson for oncologists
Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 279
Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.931 · Cited by 272
Kaufmann, M., Jonat, W., Hilfrich, J., Eidtmann, H., Gademann, G., Zuna, I., & von Minckwitz, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8054 · Cited by 267
Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., Howell, A., & On behalf of the ATAC Trialistsȁ9 Group (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9260-6 · Cited by 252
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245 · cited 3×
“Patients who experience treatmentrelated adverse effects are more likely to discontinue adjuvant endocrine therapy, particularly during the first years.(100,101) Adverse effects were the most common reason for discontinuation, particularly during the first year according to one study.”
BackgroundResultSelf-citationWhelan, T. J., Goss, P. E., Ingle, J. N., Pater, J. L., Tu, D., Pritchard, K., Liu, S., Shepherd, L. E., Palmer, M., Robert, N. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.181 · Cited by 241
Henry, N. L., Giles, J. T., Ang, D., Mohan, M., Dadabhoy, D., Robarge, J., Hayden, J., Lemler, S., Shahverdi, K., Powers, P., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9774-6 · Cited by 236
Self-citation(2008) · Cited by 225
Boccardo, F., Rubagotti, A., Guglielmini, P., Fini, A., Paladini, G., Mesiti, M., Rinaldini, M., Scali, S., Porpiglia, M., Benedetto, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl941 · Cited by 222
Bundred, N. J., Campbell, I. D., Davidson, N., DeBoer, R. H., Eidtmann, H., Monnier, A., Neven, P., von Minckwitz, G., Miller, J. C., Schenk, N. L., et al. (2008) · Cancer · doi:10.1002/cncr.23259 · Cited by 218
Self-citationSestak, I., Cuzick, J., Sapunar, F., Eastell, R., Forbes, J. F., Bianco, A. R., & Buzdar, A. U. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70182-7 · Cited by 212
Smith, I. E., Dowsett, M., Yap, Y.-S., Walsh, G., Lønning, P. E., Santen, R. J., & Hayes, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3694 · Cited by 205
Adjuvant systemic therapy for male breast carcinoma
Giordano, S. H., Perkins, G. H., Broglio, K., Garcia, S. G., Middleton, L. P., Buzdar, A. U., & Hortobagyi, G. N. (2005) · Cancer · doi:10.1002/cncr.21526 · Cited by 200
Self-citationWiner, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Self-citationAdjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198
Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey
Schrag, D., & Hanger, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2437 · Cited by 194
Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp033 · Cited by 186
Cuzick, J., Sestak, I., Cella, D., & Fallowfield, L. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70259-6 · Cited by 185
Fallowfield, L. J., Bliss, J. M., Porter, L. S., Price, M. H., Snowdon, C. F., Jones, S. E., Coombes, R. C., & Hall, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3654 · Cited by 178
Chapman, J.-A. W., Meng, D., Shepherd, L., Parulekar, W., Ingle, J. N., Muss, H. B., Palmer, M., Yu, C., & Goss, P. E. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn014 · Cited by 175
DAVIES, C. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(04)00121-5 · Cited by 170
Muss, H. B., Tu, D., Ingle, J. N., Martino, S., Robert, N. J., Pater, J. L., Whelan, T. J., Palmer, M., Piccart, M. J., Shepherd, L. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6334 · Cited by 151
Crivellari, D., Sun, Z., Coates, A. S., Price, K. N., Thurlimann, B. J. K., Mouridsen, H. T., Mauriac, L., Forbes, J., Paridaens, R., Castiglione‐Gertsch, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0459 · Cited by 144
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4482 · Cited by 140
Self-citationMouridsen, H. T., Keshaviah, A. P., Coates, A. S., Rabaglio, M., Castiglione‐Gertsch, M., Sun, Z., Thurlimann, B. J. K., Mauriac, L., Forbes, J., Paridaens, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1665 · Cited by 137
Mauriac, L., Keshaviah, A. P., Debled, M., Mouridsen, H. T., Forbes, J., Thurlimann, B. J. K., Paridaens, R., Monnier, A., Láng, I., Wardley, A. M., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm001 · Cited by 136
Cuppone, F., Bria, E., Verma, S., Pritchard, K. I., Gandhi, S., Carlini, P., Milella, M., Nisticò, C., Terzoli, E., Cognetti, F., et al. (2007) · Cancer · doi:10.1002/cncr.23171 · Cited by 122
Jakesz, R., Samonigg, H., Greil, R., Gnant, M., Schmid, M., Kwasny, W., Kubista, E., Mlineritsch, B., Tausch, C., & Stierer, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.527 · Cited by 120
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Boccardo, F., RUBAGOTTI, A., Puntoni, M., Guglielmini, P., Porpiglia, M., Mesiti, M., Rinaldini, M., Paladini, G., Distante, V., & Franchi, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.526 · Cited by 100
Hormonal therapies for early breast cancer: systematic review and economic evaluation
Hind, D., Ward, S. E., Nigris, E. D., Simpson, E. L., Carroll, C., & Wyld, L. (2007) · Health Technology Assessment · doi:10.3310/hta11260 · Cited by 93
Aromatase Inhibitor–Induced Carpal Tunnel Syndrome: Results From the ATAC Trial
Šestak, I., Sapunar, F. J., & Cuzick, J. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0236 · Cited by 91
Eisen, A. F., Trudeau, M., Shelley, W. E., Messersmith, H. J., & Pritchard, K. I. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.11.001 · Cited by 88
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
Eastell, R., Adams, J. E., Clack, G., Howell, A., Cuzick, J. M., Mackey, J. R., Beckmann, M. W., & Coleman, R. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq541 · Cited by 86
Winer, E. P., Hudis, C. A., Burstein, H. J., Bryant, J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gelber, R. D., Gralow, J. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.596 · Cited by 83
Self-citationJones, S. E., Cantrell, J., Vukelja, S. J., Pippen, J., O’Shaughnessy, J., Blum, J. L., Brooks, R. J., Hartung, N. L., Negron, A. G., Richards, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8274 · Cited by 81
Letrozole in the extended adjuvant setting: MA.17
Goss, P. E. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9698-1 · Cited by 67
Ingle, J. N., Tu, D., Pater, J. L., Muss, H. B., Martino, S., Robert, N. J., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm566 · Cited by 67
Self-citationJones, S., Seynaeve, C., Hasenburg, A., Rae, D., Vannetzel, J.-M., Paridaens, R., Markopoulos, C. J., Hozumi, Y., Putter, H., Hille, E. T. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-15 · Cited by 63
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study
Coleman, R. E., Banks, L. M., Girgis, S. I., Vrdoljak, E., Fox, J. N., Cawthorn, S., Patel, A., Bliss, J. M., Coombes, R. C., & Kilburn, L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1121-7 · Cited by 59
Lee, J.-L., Chang, C., Chueh, L.-L., & Lin, C. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9233-9 · Cited by 57
Ragaz, J., & Bence‐Bruckler, I. (2006) · Cited by 53
Aihara, T., Takatsuka, Y., Ohsumi, S., Aogi, K., Hozumi, Y., Imoto, S., Mukai, H., Iwata, H., Watanabe, T., Shimizu, C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0888-x · Cited by 51
Rea, D., Hasenburg, A., Seynaeve, C., Jones, S., Vannetzel, J. M., Paridaens, R., Markopoulos, C. J., Hozumi, Y., Putter, H., Hille, E. T. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-11 · Cited by 44
Bertelli, G., Hall, E., Ireland, E., Snowdon, C. F., Jassem, J., Drosik, K., Karnicka-Młodkowska, H., Coombes, R. C., & Bliss, J. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp358 · Cited by 41
Jakesz, R., Gnant, M., Griel, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-14 · Cited by 29
Koeberle, D., & Thuerlimann, B. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9700-y · Cited by 23
Duffy, S., Distler, W., Howell, A., Cuzick, J. M., & Baum, M. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.07.062 · Cited by 22
González-Santiago, S., Zárate, R., de la Haba-Rodríguez, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.590 · Cited by 20
Kieback, D., Harbeck, N., Bauer, W., Hadji, P., Weyer, G., Menschik, T., & Hasenburg, A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.006 · Cited by 18
Aydıner, A., & Taş, F. (2008) · Trials · doi:10.1186/1745-6215-9-47 · Cited by 18
Hadji, P., Ziller, M., Kieback, D., Dornoff, W., Tessen, H. W., Kuck, J., & Hasenburg, A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-1143 · Cited by 3
Cited by
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Metadata
- Authors
- Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., Mamounas, E. P., Rowden, D., Solky, A. J., Sowers, M. R., Stearns, V., Winer, E. P., Somerfield, M. R., & Griggs, J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-10
- Volume
- 28
- Issue
- 23
- Pages
- 3784-3796
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106286200
- Cited by
- 796
- References
- 95
- FWCI
- 25.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.